By getting their tumor genetically tested, a patient may find out that they are eligible for certain treatment options.
At this year's American Society of Clinical Oncology (ASCO) Annual Meeting, we spoke with Sarah DeBord, the communications and project manager at the Colon Cancer Coalition.
Treatment for colorectal cancer is becoming more personalized, so it is important that patients talk to their health care providers about having their tumor tested for genetic modifications such as microsatellite instability-high (MSI-H) status, which will likely be a deciding factor in the treatment that the patient gets.
